within Pharmacolibrary.Drugs.ATC.A;

model A06AX01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 1.1666666666666668e-06,
    adminDuration  = 600,
    adminMass      = 15000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0025,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A06AX01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Glycerol (glycerin) is a simple polyol compound used medically as an osmotic laxative and for reducing intracranial or intraocular pressure. It is also used in a variety of pharmaceutical formulations and as a food additive. Glycerol is approved for medical use and is broadly regarded as safe.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult healthy individuals derived from published secondary sources, as no study reports explicit compartmental model PK parameters for glycerol in humans.</p><h4>References</h4><ol><li><p>Laufen, H, et al., &amp; Yeates, RA (1986). Pharmacokinetics of oral glycerol-1-nitrate. <i>European journal of clinical pharmacology</i> 31(2) 169–175. DOI:<a href=\"https://doi.org/10.1007/BF00606654\">10.1007/BF00606654</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3100313/\">https://pubmed.ncbi.nlm.nih.gov/3100313</a></p></li><li><p>Croze, ML, &amp; Soulage, CO (2013). Potential role and therapeutic interests of myo-inositol in metabolic diseases. <i>Biochimie</i> 95(10) 1811–1827. DOI:<a href=\"https://doi.org/10.1016/j.biochi.2013.05.011\">10.1016/j.biochi.2013.05.011</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23764390/\">https://pubmed.ncbi.nlm.nih.gov/23764390</a></p></li><li><p>Tsuyusaki, H, et al., &amp; Ohwada, T (1994). Pharmacokinetics and pharmacodynamics of serum glycerol in patients with brain edema: comparison of oral and intravenous administration. <i>Acta neurochirurgica. Supplementum</i> 60 550–551. DOI:<a href=\"https://doi.org/10.1007/978-3-7091-9334-1_152\">10.1007/978-3-7091-9334-1_152</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7976647/\">https://pubmed.ncbi.nlm.nih.gov/7976647</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A06AX01;
